Vyome Holdings, Inc

ReShape Lifesciences Inc. (the “Company”) is unable, without unreasonable effort or expense, to file its Form 10-Q for the quarter ended March 31, 2025 (the “Form 10-Q”) within the prescribed time period because it requires additional time to complete the compilation of information for its financial statements and related disclosures, including to reflect the reverse stock split that was effected by the Company on May 9, 2025. The Company currently anticipates that it will file the Form 10-Q within the additional time provided by Rule 12b-25 of the Securities Exchange Act of 1934, as amended

ReShape Lifesciences Inc. (the “Company”) is unable, without unreasonable effort or expense, to file its Form 10-K for the year ended December 31, 2024 (the “Form 10-K”) within the prescribed time period because it requires additional time to complete the compilation of information for its financial statements and related disclosures. The Company currently anticipates that it will file the Form 10-K within the additional time provided by Rule 12b-25 of the Securities Exchange Act of 1934, as amended

ReShape Lifesciences Inc. (the “Company”) is unable, without unreasonable effort or expense, to file its Form 10-K for the year ended December 31, 2022 (the “Form 10-K”) within the prescribed time period because it is continuing to assess the purchase accounting from its June 2021 merger with Obalon Therapeutics Inc. (“Obalon”). The Company is in the process of completing the assessment of whether its 2021 fiscal year financial statements are materially misstated and require a restatement and the impact to the 2022 fiscal year financial statements to be included in the Form 10-K. The Company is endeavoring to complete its financial close process and Form 10-K filing as promptly as possible; however, there can be no assurance that the Company will be able to file the Form 10-K within the additional time provided by Rule 12b-25 of the Securities Exchange Act of 1934, as amended. The merger agreement with Obalon provided that Obalon would, obtain “tail” insurance policies with a claims period of at least six years from and after the effective time of the merger for the persons who were covered by the existing directors’ and officers’ liability insurance and fiduciary liability insurance of Obalon at the time of the merger agreement, with terms, conditions, retentions and levels of coverages at least as favorable as such Obalon insurance, with respect to matters existing or occurring at or prior to the effective time of the merger (the “D&O Tail Policy”). Following the merger, the Company had capitalized the D&O Tail Policy as a claims-based contract at the time of the merger and included it as an acquired asset of $1.9 million. The Company is evaluating the D&O Tail Policy to determine if the policy should have been expensed in full on the effective date, which was prior to the closing of the merger. Depending upon the final results of this analysis, the Company may be required to restate its financial statements for the year ended December 31, 2021

ed time period. ​ ReShape Lifesciences Inc. (the “Registrant”) is unable, without unreasonable effort or expense, to file its Form 10-Q for the quarter ended June 30, 2022 (the “Form 10-Q”) within the prescribed time period as it requires additional time to complete the compilation of information for its financial statements and related disclosures. The Registrant currently anticipates that it will file the Form 10-Q within the additional time provided by Rule 12b-25 of the Securities Exchange Act of 1934, as amended. ​

ed time period. ​ ReShape Lifesciences Inc. (the “Registrant”) is unable, without unreasonable effort or expense, to file its Form 10-Q for the quarter ended March 31, 2022 (the “Form 10-Q”) within the prescribed time period as it requires additional time to complete the compilation of information for its financial statements and related disclosures. The Registrant currently anticipates that it will file the Form 10-Q within the additional time provided by Rule 12b-25 of the Securities Exchange Act of 1934, as amended. ​

ed time period. ​ ReShape Lifesciences Inc. (the “Registrant”) is unable, without unreasonable effort or expense, to file its Form 10-K for the year ended December 31, 2021 (the “Form 10-K”) within the prescribed time period as it requires additional time to complete certain tax analyses related to the Registrant’s merger with Obalon Therapeutics, Inc. in June 2021, which is required in connection with its audit for the year ended December 31, 2021. The Registrant currently anticipates that it will file the Form 10-K within the additional time provided by Rule 12b-25 of the Securities Exchange Act of 1934, as amended. ​ Cautionary Statement Regarding Forward-Looking Statements ​ This document contains forward-looking statements, which are based on the Registrant’s current expectations, estimates, and projections about the Registrant’s and its subsidiaries’ businesses and prospects, as well as management’s beliefs, and certain assumptions made by management. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “may,” “should,” “will” and variations of these words are intended to identify forward-looking statements. Such statements speak only as of the date hereof and are subject to change. The Registrant undertakes no obligation to revise or update publicly any forward-looking statements for any reason. These statements include, but are not limited to, statements about the anticipated timing of the filing of the Registrant’s Form 10-K for the year ended December 31, 2021, and the Registrant’s anticipated financial results for such period. Such statements are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Accordingly, actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various factors